[go: up one dir, main page]

WO2017116092A1 - Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active - Google Patents

Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active Download PDF

Info

Publication number
WO2017116092A1
WO2017116092A1 PCT/KR2016/015241 KR2016015241W WO2017116092A1 WO 2017116092 A1 WO2017116092 A1 WO 2017116092A1 KR 2016015241 W KR2016015241 W KR 2016015241W WO 2017116092 A1 WO2017116092 A1 WO 2017116092A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
hair growth
growth
diosmin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/015241
Other languages
English (en)
Korean (ko)
Inventor
박태선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Priority to CN201680077359.6A priority Critical patent/CN108472307A/zh
Publication of WO2017116092A1 publication Critical patent/WO2017116092A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition for preventing or treating hair loss or for promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Finasteride is a drug that inhibits the 5- ⁇ -reductase enzyme, which converts testosterone into dihydrotestosterone (DHT), and serves to grow soft hair into thick and long hair. It is effective in improving hair loss in the short term, but side effects such as erectile dysfunction, decreased sexual function, and breast enlargement in men have been reported.
  • Minoxidil is a drug that can be purchased without a doctor's prescription because of its safety and effectiveness. In December 1997, it was approved by the US FDA as the first anti-hair loss treatment. This drug has the effect of promoting hair growth by improving blood circulation and opening potassium channels, but it may cause local reactions such as itching and rashes, and tachycardia.
  • the quasi-drug products that have been approved for hair loss prevention and hair growth by the KFDA include CJ Lion's 'Hair Power Competency', Moracle's 'Hair Tonic', and LG H & H's 'Mo and Moa'.
  • products are used on the scalp or hair to maintain or promote the health of the hair.
  • Human hair loss cycle is largely divided into anagen, catagen and telogen.
  • the growth phase is a time when hair growth grows rapidly due to vigorous cell division and cell division.
  • the lifespan of the growing season varies depending on the type of hair, but for hair it is about 3-6 years.
  • Growth hair accounts for 80-90% of the total hair, and hair loss is progressing in people who have a short hair growth period and a long rest period, which reduces the proportion of growth hair in the total hair.
  • the degenerative phase is the end of the growth phase of the hair and the production of the hair gradually slows down, resulting in cell division and growth stopping.
  • the degenerative lifespan is about 1-1.5 months and about 1% of the hair belongs to this stage.
  • Resting phase is the final stage of growth when hair follicles and papillae are completely separated, causing hair follicles to atrophy and hair roots to rise upwards and hair fall out.
  • the rest period lasts 3-4 months and 4-14% of all hairs fall into this stage.
  • the activity of the nipple is active again, new nipples are created, and the hair in the resting period is pushed out of the scalp.
  • Diosmin is a flavonoid glycoside (flavone) -based compound, and the name designated by the International Pure and Applied Chemical Organization (IUPAC) is 5-hydroxy-2- (3-hydroxy-4-methoxyphenyl ) -7-[(2S, 3R, 4S, 5S, 6R) -3,4,5-trihydroxy-6-[[((2R, 3R, 4R, 5R, 6S) -3,4,5-tree Hydroxy-6-methyloxan-2-yl] oxymethyl] oxan-2-yl] oxychromen-4-one [5-Hydroxy-2- (3-hydroxy-4-methoxyphenyl) -7-[(2S , 3R, 4S, 5S, 6R) -3,4,5-trihydroxy6-[[(2R, 3R, 4R, 5R, 6S) -3,4,5-trihydroxy-6-methyloxan-2-yl] oxymethyl] oxan-2-yl] oxychromen-4-
  • diosmin is a major component of the drug that is commercially available for the treatment of diseases such as chronic venous insufficiency, hemorrhoids, lymphedema, etc.
  • diseases such as chronic venous insufficiency, hemorrhoids, lymphedema, etc.
  • dermatitis, wound healing, premenstrual syndrome, viral infections, breast pain ( mastodynia, dermatofibrosclerosis, colitis, and the like (Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology.
  • the present inventors have made diligent research efforts to find naturally occurring compounds that can prevent hair loss or promote hair growth or hair growth without side effects. As a result, the present invention was completed by confirming that diosmin effectively promotes hair growth and hair growth and prevents hair loss.
  • an object of the present invention is a pharmaceutical composition for preventing or treating hair loss, or promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient; And quasi-drugs, cosmetic compositions, functional food compositions or food compositions for improving hair loss or promoting hair growth or hair growth.
  • the present invention is to provide a method for preventing or treating hair loss, or promoting hair growth or hair growth, including administering a composition comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention is to provide a use of a composition comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of hair loss, or for the preparation of hair growth or hair growth promoter.
  • the present invention provides a pharmaceutical composition for preventing or treating hair loss, or promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present inventors have made diligent research efforts to find naturally occurring compounds that can prevent hair loss or promote hair growth or hair growth without side effects. As a result, it was confirmed that diosmin effectively promotes hair growth and hair growth and prevents hair loss.
  • hair loss refers to a phenomenon in which the hair completely comes out of the scalp.
  • a person who is undergoing hair loss will have a short hair growth period and a long hair rest period.
  • diosmin converts hair from a resting period to a growing phase (FIG. 1) to prevent, improve or prevent hair loss. It has been found to be effective in treating and promoting wool.
  • hair growth refers to hair growth in the scalp
  • hair growth means that the length of the hair is increased (ie, hair growth).
  • diosmin promoted hair growth compared to the negative control (FIG. 1)
  • increased hair length by 267% (FIG. 2)
  • increased the number and diameter of hair follicles (FIGS. 3A to 3).
  • 3c increasing the expression of growth factors related to hair growth in the skin tissue (Fig. 4a, 4b, 5a and 5b) was confirmed that the hair growth promoting effect.
  • the diosmin of the present invention may be used in the form of a pharmaceutically acceptable salt, and acid salts formed by pharmaceutically acceptable free acid are useful as salts.
  • Inorganic acids and organic acids can be used as the free acid.
  • salts of diosmin of the present invention are hydrochloride, bromate, sulfate, phosphate, citrate, acetate, trifluoroacetate, lactate, tartarate, maleate, fumarate, gluconate, Methanesulfonate, glyconate, succinate, 4-toluenesulfonate, gluturonate, embonate, glutamate, or aspartate, but may be selected from the group consisting of, but is not limited thereto All salts formed using various inorganic and organic acids are included. Diosmin of the present invention may also be present in the form of solvates (eg hydrates).
  • the composition of the present invention increases ⁇ -catenin expression, Wnt10b (Wigless related MMTV integration site 10b), FZD1 (Frizzled receptor 1), LRP5 (Low-density lipoprotein receptor-related protein) 5) Increases expression of genes selected from the group consisting of Insulin-like growth factor 1 (IGF1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and keratocyte growth facfor (KGF).
  • IGF1 Insulin-like growth factor 1
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • KGF keratocyte growth facfor
  • the composition of the present invention reduces the expression of glycogen synthase kinase 3 ⁇ (GSK3 ⁇ ) or Axin.
  • the inventors of the present invention not only increase the expression of growth factors IGF1, VEGF, HGF and KGF that affect hair growth in skin tissue, but also Wnt / ⁇ -catenin signaling agents Wnt10b, FZD1, LRP5 and ⁇ It also increases catenin expression and activates the Wnt / ⁇ -catenin signaling system, which has been shown to play a pivotal role in the development and hair growth of hair follicles by confirming that the expression of GSK3 ⁇ and Axin, which are inhibited by Wnt10b, is reduced. It was confirmed at the molecular level that the composition of the present invention promotes hair growth and wool (FIGS. 5A, 5B). Therefore, the composition of the present invention can be applied as an effective hair regrowth composition showing multiple and stable hair growth promoting effects.
  • the composition of the present invention may be prepared as a pharmaceutical composition for preventing or treating hair loss, or promoting hair growth or hair growth.
  • the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen.
  • the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
  • a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mann
  • composition of the present invention may be administered orally or parenterally, according to one embodiment of the present invention, administered parenterally, and according to another embodiment of the present invention, administered by transdermal administration.
  • Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. Preferred dosages of the pharmaceutical compositions of the invention are in the range of 0.0001-100 mg / kg on an adult basis.
  • compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
  • the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.
  • the present invention provides a quasi-drug composition for improving hair loss or promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the diosmin or a pharmaceutically acceptable salt thereof may be added as it is, or may be used together with other quasi-drug components, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the quasi-drug composition of the present invention may be a disinfectant cleaner, a shower foam, a gagreen, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.
  • the present invention provides a cosmetic composition for improving hair loss, or promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to diosmin or a pharmaceutically acceptable salt thereof as the active ingredient, and include, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and Conventional adjuvants such as perfumes, and carriers.
  • the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto.
  • the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide
  • cellulose derivatives polyethylene glycols
  • silicones bentonites
  • silicas talc or zinc oxide
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the present invention provides a functional food composition or food composition for improving hair loss, or promoting hair growth or hair growth comprising diosmin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the composition of the present invention when the composition of the present invention is made of a functional food composition or a food composition, it contains not only diosmin or a pharmaceutically acceptable salt thereof as an active ingredient, but also components commonly added in the manufacture of the functional food or food, for example Examples include proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents.
  • examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol.
  • flavoring agent natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • the functional food or food composition of the present invention is prepared with a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, in addition to diosmin or a pharmaceutically acceptable salt thereof, the active ingredient of the present invention, Jujube extract or licorice extract may be further included.
  • the present invention provides a pharmaceutical composition for preventing or treating hair loss, or promoting hair growth or hair growth; And quasi-drugs, cosmetic compositions, functional food compositions or food compositions for improving hair loss or promoting hair growth or hair growth.
  • composition of the present invention not only has a natural compound having no side effects even during long-term administration of hair loss, which is a chronic disease, but also shows excellent and stable effects on hair growth and hair growth, and is effective in preventing or treating hair loss, or hair growth or It can be usefully used as a quasi-drug / cosmetics / functional food / food composition for promoting hair growth.
  • 1 is a diagram showing the results of observing the hair regrowth as the number of days of administration of each sample in the depilated mouse model.
  • Figure 3 shows the results of histological observation of the skin, such as a mouse coated with each sample for 4 weeks.
  • Figure 3a is a result of confirming the increase in the number of hair follicles
  • Figure 3b is a result of evaluating the diameter of the hair follicles
  • Figure 3c is a photograph showing the skin expression of the hair follicles.
  • Each value is the mean ⁇ standard error of 9 mice.
  • ns p > 0.05
  • ** p ⁇ 0.01 [one-way ANOVA, Tukey's test].
  • FIG. 4 shows the protein expression changes in skin tissue, such as a mouse coated with each sample.
  • 4A is an immunohistochemical result
  • FIG. 4B is a Western blot result.
  • ns p > 0.05
  • ** p ⁇ 0.01 [one-way ANOVA, Tukey's test].
  • Figure 5 is a diagram showing the change in gene expression of skin tissue, such as a mouse coated with each sample.
  • ns p > 0.05
  • * p ⁇ 0.05
  • ** p ⁇ 0.01
  • *** p ⁇ 0.001 [one-way ANOVA, Tukey's test].
  • MXD control drug minoxidil
  • DSM test material diosmin
  • mice Twenty-four male C57BL / 6N mice, 6 weeks old, were purchased from Orient Bio Co., Ltd. and adapted to the rearing room environment for two weeks, after which the negative control group (Con group), positive control group (MXD group) and diosmin group (DSM group) The experiment was divided into three groups. The animal cage was maintained at a temperature of 21 ⁇ 2.0 and a relative humidity of 50 ⁇ 5% for 12 hours at day and night. During the experiment, the mice were freely fed with a general solid chow and water.
  • Con group negative control group
  • MXD group positive control group
  • DSM group diosmin group
  • mice with resting hairs with pink dorsal skin color were used. After the hair of the back of the mouse was removed using a mouse clipper, each sample was applied once every four weeks at 4 pm.
  • the application was started, and at 1, 2, 3, and 4 weeks, the animals were lightly anesthetized with ether, and the back part was photographed.
  • the hair length was measured using a ruler to evaluate the degree of hair growth.
  • the body weight of the test animals was measured every week from just before the sample application to the time when the application was completed.
  • the initial weights of the negative control group (Con group), test group (DSM group), and positive control group (MXD group) were not significantly different between the groups, and the weights measured after 4 weeks of application were not significantly different between the experimental groups.
  • the length of the hair was measured every week during the experiment (4 weeks).
  • the hair length of the DSM group increased significantly compared to the negative control group at 2 weeks, and after 2 weeks, the hair length of the DSM group was increased by 267% (p ⁇ 0.001) (FIG. 2). Therefore, it can be seen that diosmin has an excellent effect of promoting hair growth.
  • FIG. 3 The result of measuring the number of hair follicles in each test group under an optical microscope at 40 magnification is shown in FIG. 3.
  • the number of hair follicles was significantly increased in the DSM group and the MXD group compared to the negative control group (FIG. 3A).
  • As a result of evaluating the hair follicle diameter of each test group through the image analysis it was significantly increased in the DSM group and the MXD group compared to the negative control group (Fig. 3b).
  • the DSM group and the MXD group hair follicles were prolonged and exposed to the skin, thereby confirming the hair growth promoting effect of diosmin and minoxidil (FIG. 3C).
  • RNA in skin tissue of experimental animals 1 mL of trizol solution was added to 50-100 mg of skin tissue, homogenized, and centrifuged at 4 ° C. and 12,000 ⁇ g for 10 minutes. The supernatant was transferred to a new tube and 200 ⁇ L of chloroform was added and vortexed. After repeating this process twice, the supernatant was transferred to a new tube, and isopropanol and supernatant were added at a 1: 1 ratio.
  • the concentration of the RNA sample extracted at 260 nm and 280 nm was measured using a UV / VIS spectrophotometer (Beckman coulter, DU730), and agarose gel electrophoresis was performed to confirm the integrity of the RNA sample.
  • IGF1 insulin-like growth factor 1
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • KGF keratocyte growth facfor
  • diosmin accelerates hair follicle length growth, thereby activating hair follicles back to the growth phase, and also promotes hair regrowth by increasing the expression of IGF1, HGF, VEGF and KGF in skin tissues, preventing hair loss, hair growth and hair growth. It could be seen that it promotes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour prévenir ou traiter la perte des cheveux pour stimuler la croissance des cheveux ou la restauration des cheveux ; et un quasi-médicament, une composition cosmétique, une composition d'aliment fonctionnel ou une composition d'aliment pour améliorer la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux, comprenant de la diosmine ou un sel pharmaceutiquement acceptable de celle-ci. Selon la présente invention, la composition de la présente invention contient non seulement, en tant que substance active, un composé naturel n'ayant aucun effet secondaire, même lorsqu'il est administré pendant une longue durée pour la perte des cheveux, qui est une maladie chronique, mais présente en outre des effets excellents et stables de croissance des cheveux et restauration des cheveux, de sorte que la présente invention puisse être utilement employée en tant qu'agent efficace de prévention ou de traitement de la perte de cheveux, ou en tant que composition de quasi-médicament/cosmétique/aliment fonctionnel/d'aliment pour stimuler la croissance des cheveux ou la restauration des cheveux.
PCT/KR2016/015241 2015-12-29 2016-12-23 Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active Ceased WO2017116092A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680077359.6A CN108472307A (zh) 2015-12-29 2016-12-23 包含香叶木甙作为有效成分的用于预防或治疗脱发或用于促进生发或育发的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0188799 2015-12-29
KR1020150188799A KR101725461B1 (ko) 2015-12-29 2015-12-29 디오스민을 유효성분으로 포함하는 탈모 예방 또는 치료용, 또는 발모 또는 육모 촉진용 조성물

Publications (1)

Publication Number Publication Date
WO2017116092A1 true WO2017116092A1 (fr) 2017-07-06

Family

ID=58581089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/015241 Ceased WO2017116092A1 (fr) 2015-12-29 2016-12-23 Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active

Country Status (3)

Country Link
KR (1) KR101725461B1 (fr)
CN (1) CN108472307A (fr)
WO (1) WO2017116092A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241031A1 (en) * 2019-10-17 2023-08-03 Epi Biotech Co., Ltd. Composition, Comprising Rip Kinase Inhibitor, For Preventing Hair Loss Or Promoting Hair Regrowth
CN112494506A (zh) * 2020-06-17 2021-03-16 中国药科大学 地奥司明的防脱发和生发用途
CN118078847A (zh) * 2024-04-08 2024-05-28 开远市洁白洗涤用品有限公司 一种防脱发组合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010007625A (ko) * 2000-10-06 2001-01-26 박호군 디오스민을 포함하는 동맥경화증 및 고지혈증의 예방 및치료용 조성물
EP1430933A2 (fr) * 2002-12-20 2004-06-23 Henkel Kommanditgesellschaft auf Aktien Compositions cosmétiques et pharmaceutiques comprenant des inhibiteurs de la stéroide sulfatase et leur utilisation pour diminuer la chute des cheveux
KR101269490B1 (ko) * 2012-07-09 2013-05-30 연세대학교 산학협력단 세코이리도이드 글루코사이드 유도체를 유효성분으로 포함하는 탈모의 예방 또는 치료용 조성물
KR20130103297A (ko) * 2010-04-09 2013-09-23 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물
KR20140081738A (ko) * 2012-12-21 2014-07-01 르 라보레또레 쎄르비에르 플라보이드 분획 및 잔탄 검을 포함하는 경구 현탁액 형태의 약학 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719468B1 (fr) * 1994-05-05 1996-05-31 Oreal Compositions cosmétiques à base de certains bioflavonoïdes et utilisations notamment dans le domaine capillaire.
EP2241313A1 (fr) * 2009-03-31 2010-10-20 Nestec S.A. Utilisation de flavonoïdes afin d'augmenter la biodisponibilté de l'hespérétine
CN101711768B (zh) * 2009-12-18 2012-05-30 杨义靖 地奥斯明在制造药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010007625A (ko) * 2000-10-06 2001-01-26 박호군 디오스민을 포함하는 동맥경화증 및 고지혈증의 예방 및치료용 조성물
EP1430933A2 (fr) * 2002-12-20 2004-06-23 Henkel Kommanditgesellschaft auf Aktien Compositions cosmétiques et pharmaceutiques comprenant des inhibiteurs de la stéroide sulfatase et leur utilisation pour diminuer la chute des cheveux
KR20130103297A (ko) * 2010-04-09 2013-09-23 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물
KR101269490B1 (ko) * 2012-07-09 2013-05-30 연세대학교 산학협력단 세코이리도이드 글루코사이드 유도체를 유효성분으로 포함하는 탈모의 예방 또는 치료용 조성물
KR20140081738A (ko) * 2012-12-21 2014-07-01 르 라보레또레 쎄르비에르 플라보이드 분획 및 잔탄 검을 포함하는 경구 현탁액 형태의 약학 조성물

Also Published As

Publication number Publication date
CN108472307A (zh) 2018-08-31
KR101725461B1 (ko) 2017-04-10

Similar Documents

Publication Publication Date Title
JP6563175B2 (ja) Ｖｅｇｆ産生促進剤、育毛及び／又は発毛促進剤
TWI830748B (zh) 防脫髮或毛髮生長促進用組合物
JP7748548B2 (ja) 脱毛防止又は発毛促進活性を有するペプチドとその用途
WO2020262933A1 (fr) Composition pharmaceutique pour prévenir la chute des cheveux ou favoriser la pousse des cheveux, comprenant du ginsénoside rg4 ou un mélange (rgx 365) de ginsénosides rg2, rg4, rg6 et rh1 en tant que principe actif
PH12016500067B1 (en) Composition for promoting hair sprouting and hair growth
JP6145106B2 (ja) 精製したセコイリドイドグルコシド誘導体からなる発毛促進剤、ＩＧＦ−１発現増加剤、ＶＥＧＦ発現増加剤、ＨＧＦ発現増加剤、ＫＧＦ発現増加剤、およびβ−カテニン発現増加剤
WO2017116092A1 (fr) Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active
WO2018070706A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser leur pousse comprenant du décanal ou un sel pharmaceutiquement acceptable de celui-ci à titre de principe actif
WO2022045635A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de lagerstroemia indica en tant que principe actif
JP2015107925A (ja) ムスカリン受容体活性化剤及び唾液分泌促進剤
WO2024210460A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux ou atténuant la chute des cheveux et son utilisation
BR112020002216B1 (pt) Uma composição sinérgica como um promotor de autofagia
WO2016060298A1 (fr) Composition contenant une substance pour la régulation de l'expression d'antigènes abh
KR101587612B1 (ko) 피노카베올을 유효성분으로 포함하는 탈모 예방 또는 치료용, 또는 발모 또는 육모 촉진용 조성물
WO2019031655A1 (fr) Composition comprenant du thymol comme principe actif pour prévenir ou traiter les rides de la peau ou la dermatite atopique
WO2018030560A1 (fr) Composition pour prévenir, améliorer ou traiter la perte des cheveux, comprenant de l'acide désoxycholique comme principe actif
JP2024537698A (ja) 脱毛防止又は発毛促進活性を有するペプチドとその用途
WO2023055053A1 (fr) Peptide ayant une activité de prévention de la chute des cheveux ou de favorisation de la pousse des cheveux et son utilisation
EP3829626B1 (fr) Extrait de lespedeza capitata pour son utilisation dans le domaine capillaire
EP1620116B1 (fr) Utilisation du quinquina pour la preparation d'un medicament stimulant l'angiogenese
WO2022092495A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'une maladie immunitaire du type hypersensibilité contenant du galactose
KR101906896B1 (ko) 티몰 및 미르센을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물
JP2016079152A (ja) エストロゲン受容体β活性化剤
WO2021107414A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter des maladies dépendantes des androgènes, contenant un extrait de feuille de bambou en tant que principe actif
CN105658094A (zh) 植物提取物用于预防和治疗脱发的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16882044

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16882044

Country of ref document: EP

Kind code of ref document: A1